Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
PT-141
FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women. Prescription only.
Tier Alow risk
02· Subject
Oxytocin
Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.
Tier Amed-high risk
01 · At a glance
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Primary fit | sexual health & libido research where you want a clear starting point | sexual health & libido and anxiety & mood comparisons | sexual health & libido research where you want a clear starting point |
| Evidence | Tier A | Tier A | Tier B |
| Risk | low | med-high | medium |
| Experience level | advanced | advanced | advanced |
| Budget tier | premium | mid | premium |
| Administration route | subcutaneous | intranasal, intravenous | intravenous, subcutaneous |
02 · Use case & timing
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Goal fit | Sexual Health & Libido | Sexual Health & Libido, Anxiety & Mood | Sexual Health & Libido |
| What users compare it for | Improved sexual desire in premenopausal women with acquired generalized HSDD. | Social cognition, bonding, anxiety modulation effects in research settings. | LH/FSH axis stimulation; fertility research applications. |
| Onset timeline | Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose. | Acute effects studied within hours post-dose; mixed efficacy across conditions. | Acute LH response within ~45 minutes; fertility endpoints context-specific. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Adverse effects | Nausea, flushing, injection site reactions, headache, vomiting. BP elevation. | Generally minimal at trial doses; vulnerable populations require caution. | FDA: limited safety data, immunogenicity concerns for compounding. |
| Contraindications | Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products. | Rx product; clinical supervision required. | No formal label; high endocrine interaction potential. |
| Interaction notes | Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone. | No uniform interaction map; treat as Rx/clinical research context. | High endocrine interaction potential with GnRH analogues and gonadotropins. Do not provide stacking guidance. |
| Regulatory status | Prescription-approved | Prescription-approved | Not approved |
| FDA flag | No current flag noted | No current flag noted | FDA compounding caution |
| WADA status | Not listed | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64 | No age guidance yet | No age guidance yet |
| Life-stage note | Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern. | Not yet documented | Not yet documented |
| Monitoring burden | medium | Not specified | Not specified |
| Follow-up cadence | Review tolerance early and reassess if use becomes frequent. | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Typical cycle cost | €27.29 | No reliable estimate yet | No reliable estimate yet |
| Estimated monthly cost | €27.29 | No reliable estimate yet | No reliable estimate yet |
| Cost confidence | High confidence | No estimate | No estimate |
06 · Before you buy
| Decision factor | PT-141 | Oxytocin | Kisspeptin |
|---|---|---|---|
| Tracked vendor listings | 3 listings | 1 listing | 0 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Tracked product pages are available, which makes it easier to review the listing before you click out. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Better as a standalone decision | Better as a standalone decision | Better as a standalone decision |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.